FDA
-
-
-
-
-
-
-
Exact Sciences (EXAS) Reports Prelim Q4 Results
-
-
-
-
-
-
-
Next-Generation CologuardĀ® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detectio
-
-
-
-
-
-
-
Exact Sciences (EXAS) Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing
-
-
-
-
-
-
-
Exact Sciences (EXAS) Guides Q4 Revenue of $551-$553M
-
-
-
-
-
-
-
Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress
-
-
-
-
-
-
-
Exact Sciences (EXAS) Reports Data Showing Improved Accuracy of Second-generation Cologuard Test
-
-
-
-
-
-
-
Scipher MedicineĀ® Appoints Sam Asgarian, M.D., MBA Chief Medical Officer
-
251,413 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All